Advertisement

Pfizer and BioNTech begin testing Omicron-specific COVID-19 vaccine

Click to play video: 'COVID-19: 2 doses of Pfizer vaccine protects 70% against hospitalization from Omicron, study shows' COVID-19: 2 doses of Pfizer vaccine protects 70% against hospitalization from Omicron, study shows
A new real-world study released this week found two doses of the Pfizer-BioNTech COVID-19 vaccine provides 70 per cent protection against hospitalization by the Omicron variant – Dec 14, 2021

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the  protection provided by the original two-dose vaccine regimen.

The companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.

Read more: COVID-19 vaccine rate for children remains low amid Omicron wave

They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received their third dose of the Pfizer/BioNTech vaccine three to six months earlier.

The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.

Story continues below advertisement
Click to play video: 'COVID-19: Canada’s top doctor lays out groups prioritized for Pfizer’s antiviral pill' COVID-19: Canada’s top doctor lays out groups prioritized for Pfizer’s antiviral pill
COVID-19: Canada’s top doctor lays out groups prioritized for Pfizer’s antiviral pill – Jan 17, 2022

“While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,” Pfizer’s head of vaccine research and development, Kathrin Jansen, said in a statement.

Pfizer has said that a two-dose regimen of the original vaccine may not be sufficient to protect against infection from the Omicron variant, and that protection against hospitalizations and deaths may be waning.

Read more: Annual COVID-19 booster preferable to frequent shots, Pfizer CEO says

Still, the U.S. Centers for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer/BioNTech vaccine has provided 90 per cent protection against hospitalization due to COVID-19.

Story continues below advertisement

Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent infection by the Omicron variant.

(Reporting by Michael Erman; Editing by Leslie Adler)

Sponsored content